1.上海中医药大学附属岳阳中西医结合医院,上海市虹口区甘河路110号
2.上海市光华中西医结合医院
haiyin_huang@126.com
收稿:2022-08-21,
修回:2022-12-18,
纸质出版:2023-03-17
移动端阅览
王明莉,毛灵,訾素娜等.清热中药对支气管扩张症稳定期患者临床症状及生活质量的影响——一项50例单病例随机对照研究[J].中医杂志,2023,64(06):600-608.
WANG Mingli,MAO Ling,ZI Suna,et al.Effects of Heat-clearing Chinese Medicinals on Clinical Symptoms and Quality of Life in Stable Bronchiectasis:N-of-1 Trials of 50 Cases[J].Journal of Traditional Chinese Medicine,2023,64(06):600-608.
王明莉,毛灵,訾素娜等.清热中药对支气管扩张症稳定期患者临床症状及生活质量的影响——一项50例单病例随机对照研究[J].中医杂志,2023,64(06):600-608. DOI: 10.13288/j.11-2166/r.2023.06.011.
WANG Mingli,MAO Ling,ZI Suna,et al.Effects of Heat-clearing Chinese Medicinals on Clinical Symptoms and Quality of Life in Stable Bronchiectasis:N-of-1 Trials of 50 Cases[J].Journal of Traditional Chinese Medicine,2023,64(06):600-608. DOI: 10.13288/j.11-2166/r.2023.06.011.
目的
2
比较个体化方、个体化减清热方的疗效与安全性差异,评价清热中药在支气管扩张症稳定期的价值。
方法
2
采用随机、双盲的单病例随机对照试验方法,对50例支气管扩张症稳定期患者进行3轮试验,每轮试验期和对照期各4周。患者在试验期服用辨证施治的个体化方,对照期服用个体化减清热方(在个体化方中去除清热中药),每一期服药3周,停药1周进行指标采集。主要结局指标为总体症状(Likert量表)评分,次要结局指标为慢性阻塞性肺疾病评估测试(CAT)评分、24 h痰量。分别采用配对
t
检验和Meta分析评估不同方剂的个体及群体疗效差异。
结果
2
个体水平上,6例Likert量表评分、1例24 h痰量个体化方优于个体化减清热方(
P
<0.05)。群体数据Meta分析结果显示,在总体症状评分[
MD
=-0.10,95%
CI
(-0.13,-0.06)(
P
<0.01)]、CAT评分[
MD
=-0.48,95%
CI
(-0.86,-0.11)(
P
=0.01)]、24 h痰量[
MD
=-0.48,95%
CI
(-1.29,0.04)(
P
=0.07)]上个体化方均优于个体化减清热方。两种方剂均未出现严重不良反应。
结论
2
清热中药可减轻支气管扩张症稳定期患者临床症状,提高生活质量,安全性良好,但较不使用清热中药疗效提高程度有限。
Objective
2
To compare the differences in the efficacy and safety of the individualized decoctions and the individualized decoctions that removed of heat-clearing medicinals, and to evaluate the value of heat-clearing Chinese medicinals in the stable stage of bronchiectasis.
Methods
2
Fifty patients in the stable stage of bronchiectasis were enrolled in a double-blind, randomized, N-of-1 trials. The trial was consisted of three rounds, each round having testing period and control period, 4 weeks respectively. Patients took individualized decoction based on syndrome differentiation during the testing period, and took individualized decoction that removed heat-clearing medicinals during the control period. The medication time during each period was three weeks, and the primary outcome measures including overall symptom score (Likert scale), secondary outcome including chronic obstructive pulmonary disease assessment test (CAT) score and 24-hour sputum volume were evaluated one week after stopping medication. Paired
t
-test and meta-analysis were used to evaluate the efficacy differences of different prescriptions at the individual and group level.
Results
2
At the individual level, there were statistically significant differences in favor of individualized decoction than that removing heat-clearing medicinals in the Likert scale score (6 cases) and 24-hour sputum volume (1 case) of certain patients (
P
<0.05). At the group level, the results of meta-analyses showed that individualized decoction was better than that removing the heat-clearing medicinals in overall symptom score (
MD
= -0.10, 95%
CI
-0.13, -0.06,
P
<0.001), CAT score (
MD
= -0.48, 95%
CI
-0.86, -0.11,
P
= 0.01) and 24-hour sputum volue (
MD
= -0.48, 95%
CI
-1.29, 0.04,
P
= 0.07). There were no serious adverse reactions of the two TCM prescriptions.
Conclusion
2
Heat-clearing Chinese medicinals can relieve symptoms and improve quality of life in patients with stable bronchiectasis with good safety, but the degree of improvement is limited.
支气管扩张症专家共识撰写协作组 , 中华医学会呼吸病学分会感染学组 . 中国成人支气管扩张症诊断与治疗专家共识 [J]. 中华结核和呼吸杂志 , 2021 , 44 ( 4 ): 311 - 321 .
李建生 , 王至婉 , 谢洋 , 等 . 支气管扩张症中医证候诊断标准(2019版) [J]. 中医杂志 , 2020 , 61 ( 15 ): 1377 - 1380 .
黄海茵 , 杨佩兰 , 汤杰 , 等 . 扶正化痰清热法治疗支气管扩张症46例远期疗效观察 [J]. 中医杂志 , 2012 , 53 ( 10 ): 848 - 852 .
毛灵 , 张谊 , 张恩丝 , 等 . 清热中药对支气管扩张症抑菌作用的研究进展 [J]. 世界科学技术-中医药现代化 , 2022 , 24 ( 1 ): 345 - 350 .
陈蔚文 . 中药学 [M]. 北京 : 人民卫生出版社 , 2002 : 66 .
訾素娜 , 杨佩兰 , 徐敏华 , 等 . 清热中药在支气管扩张症稳定期作用的个体化研究 [J]. 世界科学技术-中医药现代化 , 2019 , 21 ( 9 ): 1948 - 1955 .
商洪才 , 田贵华 . 单病例随机对照试验 [M]. 北京 : 人民卫生出版社 , 2019 : 1 - 9 .
成人支气管扩张症诊治专家共识编写组 . 成人支气管扩张症诊治专家共识 [J]. 中华结核和呼吸杂志 , 2012 , 3 ( 5 ): 485 - 492 .
POLVERINO E , GOEMINNE PC , MCDONNELL MJ , et al . European Respiratory Society guidelines for the management of adult bronchiectasis [J]. Eur Respir J , 2017 , 50 ( 3 ): 1700629 .
国家中医药管理局 . 中医病证诊断疗效标准 [S]. 南京 : 南京大学出版社 , 1994 : 4 .
张惠勇 , 李欣 , 倪伟 , 等 . 支气管扩张证中医辨证分型规律的研究 [J]. 上海中医药杂志 , 2005 , 39 ( 1 ): 16 - 18 .
邵长荣 . 邵长荣实用中医肺病学 [M]. 北京 : 中国中医药出版社 , 2009 : 199 - 201 .
GUYATT G , RENNIE D . Users' guides to the medical literature: essentials of evidence-based clinical practice, second edition [M]. Chicago : AMA Press , 2002 : 3 - 11 .
LEE BY , LEE S , LEE JS , et al . Validity and reliability of CAT and dyspnea-12 in bronchiectasis and tuberculous destroyed lung [J]. Tuberc Respir Dis(Seoul) , 2012 , 72 ( 6 ): 467 - 474 .
V 0 HRA S , SHAMSEER L , SAMPSON M , et al . CONSORT extension for reporting N-of-1 trials(CENT) 2015 Statement [J]. J Clin Epidemiol , 2016 , 7 ( 6 ): 9 - 17 .
LI J , HU JY , ZHAI JB , et al . CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine(CENT for TCM) : Recommendations, explanation and elaboration [J]. Complement Ther Med , 2019 , 4 ( 6 ): 180 - 188 .
ZI SN , HUANG HY , YANG PL , et al . Evaluating the effects of heat-clearing traditional Chinese medicine in stable bronchiectasis by a series of N-of-1 trials [J]. Evid Based Complement Alternat Med , 2022 : 6690638 . doi: 10.1155/2022/6690638 http://dx.doi.org/10.1155/2022/6690638 .
GUYATT GH , KELLER JL , JAESCHKE R , et al . The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience [J]. Ann Intern Med , 1990 , 112 ( 4 ): 293 - 299 .
王明莉 , 王振伟 , 陈新林 , 等 . 单病例试验的方法学比较和临床应用探索 [J]. 中国循证医学杂志 , 2022 , 22 ( 4 ): 468 - 474 .
LU LZ , AN JQ , CHEN HJ , et al . A series of N-of-1 trials for traditional Chinese medicine using a bayesian method: study rationale and protocol [J]. Evid Based Complement Alternat Med , 20211 : 9976770 . doi: 10.1155/2021/9976770 http://dx.doi.org/10.1155/2021/9976770 .
0
浏览量
0
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号